Sponsor:
Massachusetts General Hospital
Code:
NCT05417776
Conditions
Interstitial Lung Disease
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Interventions
[68Ga]CBP8
Dotarem
Brief summary:
Conditions
Interstitial Lung Disease
Study ID
NCT05417776
Start date
Sep 28, 2022
Status verified date
Apr, 2026
Completion date
Dec 1, 2026
Anticipated
Primary completion date
Oct 1, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Enrollment
30 participants
Anticipated
Allocation
Non randomized
Intervention Model
Parallel Assignment
Primary purpose
Diagnostic
Arms
experimental: Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD)
experimental: First degree relatives of a family member with pulmonary fibrosis
Interventions
[68Ga]CBP8
Dotarem
Primary outcome measure
Central contacts
Locations
Massachusetts General Hospital
Recruiting
Boston, Massachusetts, United States, 02114
Principal Investigator:
Sydney Montesi, MD
Sponsor
Massachusetts General Hospital
Last update posted
Apr 20, 2026
Last verified
Apr, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Massachusetts General Hospital on 2026-04-20.